Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application

Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application While radioimmunotherapy (RIT) for the treatment of hematological malignancies such as indolent B‐cell lymphoma has proven quite successful, clinical results of RIT in solid tumors have only been moderate in the past. The reasons were manifold and can be mostly attributed to the different biological properties of solid tumors vs hematological cancers. Furthermore, the slow clearance of the radiolabelled antibody prevents the use of radiation doses necessary to achieve clinical responses. The long biological half‐life of radioimmunoconjugates results in high background levels and is the main reason for radiation related toxicities. In recent years, researchers and clinicians have developed solutions for the successful application of RIT for the treatment of solid tumors. These include compartmental route of administration, neoadjuvant therapies, and pretargeting approaches. In this review, recent developments in RIT for the treatment of solid tumors that address these restrictions as well as future perspectives will be highlighted from a clinical perspective. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Labelled Compounds and Radiopharmaceuticals Wiley

Radioimmunotherapy of solid tumors: Approaches on the verge of clinical application

Download PDF
12 pages

Loading next page...
 
/lp/wiley/radioimmunotherapy-of-solid-tumors-approaches-on-the-verge-of-clinical-u9wF8Zo7ps

References (56)

Publisher
Wiley
Copyright
© 2018 John Wiley & Sons, Ltd.
ISSN
0362-4803
eISSN
1099-1344
DOI
10.1002/jlcr.3619
Publisher site
See Article on Publisher Site

Abstract

While radioimmunotherapy (RIT) for the treatment of hematological malignancies such as indolent B‐cell lymphoma has proven quite successful, clinical results of RIT in solid tumors have only been moderate in the past. The reasons were manifold and can be mostly attributed to the different biological properties of solid tumors vs hematological cancers. Furthermore, the slow clearance of the radiolabelled antibody prevents the use of radiation doses necessary to achieve clinical responses. The long biological half‐life of radioimmunoconjugates results in high background levels and is the main reason for radiation related toxicities. In recent years, researchers and clinicians have developed solutions for the successful application of RIT for the treatment of solid tumors. These include compartmental route of administration, neoadjuvant therapies, and pretargeting approaches. In this review, recent developments in RIT for the treatment of solid tumors that address these restrictions as well as future perspectives will be highlighted from a clinical perspective.

Journal

Journal of Labelled Compounds and Radiopharmaceuticals – Wiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

There are no references for this article.